[{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ Clinipace Worldwide","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Clinipace Worldwide"},{"orgOrder":0,"company":"Ann & Robert H Lurie Children's Hospital of Chicago","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"Ann & Robert H Lurie Children's Hospital of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ann & Robert H Lurie Children's Hospital of Chicago \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Ann & Robert H Lurie Children's Hospital of Chicago \/ On Target Laboratories"},{"orgOrder":0,"company":"Indiana University","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indiana University \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Indiana University \/ On Target Laboratories"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Irvine \/ On Target Laboratories"}]

Find Clinical Drug Pipeline Developments & Deals for Pafolacianine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of California, Irvine

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          University of California, Irvine

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 19, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Indiana University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Indiana University

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Ann & Robert H Lurie Children's Hospital of Chicago

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Ann & Robert H Lurie Children's Hospital of Chicago

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 31, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Cytalux (pafolacianine) is an FDA-approved optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

                          Product Name : Cytalux

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 05, 2022

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          January 27, 2020

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Clinipace Worldwide

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          June 08, 2017

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 19, 2016

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Medelis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          December 16, 2014

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank